Google
Trusted Resources: News & Events
Latest announcements and gatherings
Novartis acquires US pharma research firm Selexys Pharmaceuticals
Swiss-based pharmaceuticals giant Novartis said Monday it was acquiring Selexys Pharmaceuticals Corp., a US research lab in blood and inflammatory disorders, in a deal costing up to $665 million (627 million euros).
Selexys specialises in sickle cell disease, an inherited form of anaemia that is most common among people of African descent.
In a statement, Novartis said it exercised rights to buy the company after seeing results from a large trial into a drug to treat pain for people with the disease.
+myBinderRelated Content
-
Predictive factors of daily opioid use and quality of life in adults with sickle cell diseaseObjectives: In adults with sickle cell ...
-
Bone Marrow Transplantation: A Treatment Option for Sickle Cell DiseaseBone marrow transplantation is the only ...
-
A Teenager’s Breakthrough Gene Therapy for Sickle Cell DiseaseMeet Helen Obando, a shy 16-year-old who...
-
SCA Therapy Hydroxyurea Doesn’t Boost Malaria Risk in Sub-Saharan Africa, Study FindsHydroxyurea, a treatment recommended for...
-
L-glutamine Oral Powder Significantly Reduces Acute Complications of Sickle Cell DiseaseApproved by the US Food and Drug...
-
Sickle Cell Disease Association of America, Inc. and Hemanext® Inc. Form New Strategic PartnershipSickle Cell Disease Association of Ameri...
-
Sickle Cell Patient Receives CRISPR Gene TherapyMany human diseases can be traced back t...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.